View in Other Languages

Mesoblast Limited

ASX:MSB ISIN:AU000000MSB8

 Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

  

News

Mesoblast Limited (ASX:MSB) FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes

🕔1/31/2012 11:09:00 AM 5624

Mesoblast Limited (ASX:MSB) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its proprietary adult stem cells for the treatment of Type 2 diabetes.

Read Full Article

Corporate Strategy Key to Mesoblast Limited (ASX:MSB) Success

🕔11/24/2011 11:24:00 AM 6422

Mesoblast Limited (ASX:MSB) Chief Executive, Professor Silviu Itescu, today provided shareholders at Mesoblast's Annual General Meeting with an overview of the company's corporate strategy and major highlights of recent achievements.

Read Full Article

Mesoblast Limited (ASX:MSB) 2011 Chairman's Address and CEO's Presentation to Shareholders

🕔11/24/2011 9:48:00 AM 8716

Mesoblast Limited (ASX:MSB) Chairman's Address and CEO's Presentation to Shareholders

Read Full Article

Positive Outcome From FDA Meeting For Type 2 Diabetes Clinical Program Using Intravenous Delivery of Mesoblast Limited (ASX:MSB) Proprietary Adult Stem Cells

🕔11/22/2011 10:08:00 AM 6413

Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell (MPC) technology in patients with Type 2 Diabetes. Based on the positive outcome of the FDA meeting held on November 18, Mesoblast will file an Investigational New Drug (IND) submission within the next 30-60 days to seek clearance for patient recruitment.

Read Full Article

Mesoblast Limited (ASX:MSB) Presented Positive Results from Phase 2 Trial of Adult Stem Cell Therapy at the American Heart Association Annual Meeting

🕔11/15/2011 8:25:00 AM 6629

Regenerative medicine company Mesoblast Limited (ASX:MSB) today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor(TM) after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months. The Phase 2 trial results in 60 patients were presented at the American Heart Association annual meeting in Orlando, Florida, by the trial's independent principal investigator Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute in Houston.

Read Full Article

Mesoblast Limited (ASX:MSB) Reports Positive Results Using Intravenously Injected Adult Stem Cells for Type 2 Diabetes

🕔11/10/2011 8:27:00 AM 6375

Regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by significant reductions in circulating inflammatory markers to levels associated with protection against heart attacks and death in patients with Type 2 diabetes. Results of the study were presented at the Credit Suisse Healthcare conference in Phoenix, Arizona.

Read Full Article

Mesoblast Limited (ASX:MSB) Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases

🕔10/24/2011 9:48:42 AM 5200

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes - neovascular ("wet") Age-related Macular Degeneration (AMD). Wet AMD causes sudden and severe central vision loss and accounts for approximately 90 percent of all blindness in the elderly. Mesoblast is developing a stem cell therapeutic product for treating various vascular diseases of the eye, including wet AMD and diabetic macular edema (DME).

Read Full Article

Mesoblast Limited (ASX:MSB) Received Licensing Executives Society 2011 Deals of Distinction(TM) Award

🕔10/20/2011 10:21:00 AM 5597

Mesoblast Limited (ASX:MSB) and its strategic alliance partner Cephalon Inc. were today awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction(TM) Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences sector.

Read Full Article

Mesoblast Limited (ASX:MSB) and Lonza Group (VTX:LONN) Form Strategic Global Manufacturing Alliance

🕔9/27/2011 8:27:00 AM 4642

Global regenerative medicine company Mesoblast Limited (ASX:MSB) and Lonza Group (VTX:LONN), a world leader in biologic manufacturing, today announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast's off-the-shelf (allogeneic) adult stem cell products.

Read Full Article

Mesoblast Limited (ASX:MSB) Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks

🕔9/5/2011 8:36:00 AM 5899

Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor(TM) is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks.

Read Full Article
###

170,332 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 91) (Last 30 Days: 432) (Since Published: 46643) 

Company Data

    Headquarters
  • Level 39
    55 Collins Street
    Melbourne 3000
    AUSTRALIA
  • Telephone
  • +61-3-9639-6036 
  • Fax
  • +61-3-9369-6030 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2004/12/16 
  • Homepage
  • www.mesoblast.com

Presentations

Social Media